Novartis completed the acquisition of Regulus Therapeutics for $1.7bn.

Novartis, a company specializing in global healthcare solutions, completed the acquisition of Regulus Therapeutics, a clinical-stage biopharmaceutical company, for $1.7bn. “We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-class medicine that can help treat patients suffering from ADPKD (autosomal dominant polycystic kidney disease), the most common genetic cause of renal failure worldwide. We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need," Shreeram Aradhye, Novartis President, Development and Chief Medical Officer.